IPI-269609

IPI-269609 is an orally effective Smoothed (SMO) inhibitor that targets the Hedgehog (Hh) signaling pathway. IPI-269609 specifically reduces the ALDH-bright (high aldehyde dehydrogenase activity) cell subset, which is considered the "cancer stem cells" in pancreatic cancer. IPI-269609 significantly inhibits the migration and colony formation of pancreatic cancer cells. IPI-269609 effectively inhibits pancreatic cancer metastasis in a mouse model. IPI-269609 can be used for pancreatic cancer research[1].

Product Specifications

CAS Number

[878204-96-7]

UNSPSC

12352005

Target

Hedgehog; Smo

Related Pathways

Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C1CC[C@]2(C)[C@@]3([H])CC4=C(C)C[C@]([C@@H]5C)(CC[C@@]4([H])[C@]3([H])CCC2=C1)O[C@@]6([H])[C@@]5([H])NC[C@@H](C)C6

Molecular Formula

C28H41NO2

Molecular Weight

423.63

References & Citations

[1]Feldmann G, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther. 2008 Sep;7 (9) :2725-35.